Press Releases

Positive results from the Phase 2-3 COVA study presented at the 21st ERS 2023 Lung Science Conference .Biophytis announced that it presents the positive results of the phase 2-3 COVA study with Sarconeos (BIO101) in severe COVID-19 at the European Respiratory Society 2023 21st Lung Science Conference taking place in Estoril, Portugal, between the 9th and the 12th of March 2023. Professor Suzana Lobo, MD – Hospital de Base Da Faculdade de Medicina de São José Do Rio Preto, São Paulo, Brazil and Investigator of the COVA study in Brazil, will be holding an oral presentation of the results titled

Biophytis announces the signature of a master service agreement with Intsel Chimos, a pharmaceutical company that will operate Sarconeos (BIO101) in France for the treatment of severe forms of COVID-19 Biophytis and Intsel Chimos signed a master service agreement under which Intsel Chimos will be the operating pharmaceutical company/exploitant, partner and distributor in France for the drug Sarconeos (BIO101) developed by Biophytis in the context of the early access program application. The application request for early access program, currently underway with the Haute Autorité de Santé (the French National Authority for Health, HAS), aims to allow treatment with Sarconeos (BIO101)

Biophytis initiates the regulatory process for an early access authorization in France from the French National Authority for Health (HAS) for the treatment with Sarconeos (BIO101) of severe forms of COVID-19 Biophytis announced that it has begun the process of early access application in France from the French National Authority for Health (HAS) for the treatment of severe COVID-19 with Sarconeos (BIO101). A pre-submission meeting with the HAS is scheduled for March and the application for early access authorisation should be submitted shortly after with the aim of obtaining authorisation in the second quarter of 2023. This programme would allow

Biophytis announced it is convening an Extraordinary and Ordinary Shareholders’ Meeting for March 30, 2023 Delegation to the Board of Directors to reduce the nominal value Regrouping of the company’s shares Renewal of Authorizations granted at the June 2022 AGM Stanislas Veillet, CEO of Biophytis, stated: “Following COVA study positive results, we now wishe to regain the leeway and tools to refinance the company. We therefore ask shareholders to allow us to reduce the “par value” of the share within the limit of the company’s losses and for a minimum value of €0.002. This reduction in the nominal value will

Biophytis announces positive final results of the phase 2-3 COVA study with Sarconeos (BIO101) in severe COVID-19 COVA study met primary end point with 44% significant reduction in the risk of respiratory failure or early death. Filing for Early Access Programs to Sarconeos (BIO101) is being initated while preparing for Marketing Authorisation in Europe and the USA. Fullscreen Mode

Biophytis publishes its interim financial report for the first half of 2022 and its adjusted financial results as of 31 December 2021 Biophytis publishes its interim financial report for the first half of 2022 and its adjusted financial results as of 31 December 2021. Fullscreen Mode

Judgment of the Paris Court of Appeal of 17 January 2023 in the case between Biophytis and Negma Group Ltd The Paris Court of appeal confirms the judgement of the Paris Conmmercial Court of 16th of March 2021 Fullscreen Mode

Biophytis announces its participation in two major investor conferences in January, in the United States and in France: the JP Morgan Healthcare Conference and the Invest Securities Biomed Event.

Following the positive post-hoc analysis of the phase 2-3 COVA clinical study strongly supporting therapeutic potential of Sarconeos (BIO101) in the treatment of pneumonia in COVID-19 patients at risk of respiratory failure, Biophytis management is inviting all of Biophytis’ stakeholders to an online event with KOL.

Biophytis reports positive post-hoc analysis of the phase 2-3 COVA clinical study strongly supporting therapeutic potential of Sarconeos (BIO101) in COVID-19 Biophytis released the full results from its phase 2-3 COVA clinical study evaluating Sarconeos (BIO101) in the treatment of COVID-19-related respiratory failure.  A reduction in the risk of early death or respiratory failure at day 28 of 45% in the Intent-To-Treat (ITT) population and 53% in the Per Protocol (PP) population A reduction in the risk of death at day 90 of 43% in the ITT population and 70% in the PP population The start of regulatory development of